A Phase Ia, Randomized, Double-blind, Placebo-controlled, Single Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HB0043 in Healthy Adult Subjects
Latest Information Update: 05 Jun 2025
At a glance
- Drugs HB 0043 (Primary)
- Indications Autoimmune disorders; Pustular psoriasis; Systemic lupus erythematosus; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Huaota Biopharmaceuticals
Most Recent Events
- 05 Jun 2025 New trial record